HUBUNGAN IMUNOTERAPI DOSIS ESKALASI TERHADAP PERUBAHAN RASIO IL-4/IFN-Y DAN PERBAIKAN GEJALA KLINIK PENDERITA RINITIS ALERGI

Abstract

Background : immunotherapy escalation dose induces Th1 immune responses. Th1 and Th2 cells are reciprocally regulated, that means the increasing of Th1 immune may be inhibited by Th2 immune responses and inversely. Allergic rhinitis is a disease which marked by a predominant Th2 responses. Objective : to know the relationship of immunotherapy escalation doses with ratio IL- and its clinical benefit. Methods : this was 8 weeks clinical trial, randomized control group pretest-posttest design. A moderate/severe grade of allergic rhinitis patients divided into two groups. The ITS group, the sample received immunotherapy escalation doses and the control group received symptomatic drugs. The IL-4 and level were evaluated pre and post study. The clinical symptom scores were assessed everyday during the study, as well as the medication days. Result : 42 moderate/severe grade allergic rhinitis patients were included this study (ITS = 21; control=21). The IL-4 and level as well as ratio IL-4/ pre and posttest treatment were not significantly different in ITS group and control group (p > 0.05). The IL-4 and level as well as ratio IL-4/ between groups were not significantly different ( p > 0.05). The clinical symptom scores during pre and post treatment in both group and between groups were significantly different ( p < 0.01). The cumulative of asymptomatic and comfortable days were significantly different in ITS group. The medication days between groups were not significantly different (p > 0,05) although in ITS group they were less than control group. Conclusion: immunotherapy escalation dose did not decrease IL-4/ ratio, but can improve the clinical symptoms of allergic rhinitis. Key words : allergic rhinitis, immunotherapy escalation doses, rasio IL